
Choosing a Medicare Advantage Plan That's Right for You
There are many factors to consider when choosing a Medicare Advantage (Part C) plan, including costs, in-network providers, and coverage for medical services and prescription medications.
If you're shopping for a Medicare Advantage (Part C) plan this year, you may wonder what the best plan is for you. It depends on your personal situation, medical needs, how much you can afford, and other factors.
Tools are available to help you find Medicare Advantage plans in your area that can meet all your healthcare needs.
Glossary of common Medicare terms
Out-of-pocket cost: This is the amount you pay for care when Medicare doesn't pay the full cost or offer coverage. It includes premiums, deductibles, coinsurance, and copayments.
Premium: This is the monthly amount you pay for Medicare coverage.
Deductible: This is the annual amount you must spend out of pocket before Medicare begins to cover services and treatments.
Coinsurance: This is the percentage of treatment costs you're responsible for paying out of pocket. With Medicare Part B, you typically pay 20%.
Copayment: This is a fixed dollar amount you pay when receiving certain treatments or services. With Medicare, this often applies to prescription medications.
Factors to consider when choosing a Medicare Advantage plan
With all the changes being made to the Medicare plans on the market, it can be hard to narrow down the best plan for you.
Here are a few things to look for in a Medicare Advantage plan:
costs that fit your budget and needs
a list of in-network providers that includes any doctor(s) you would like to keep
coverage for services and medications you know you'll need
Centers for Medicare & Medicaid Services (CMS) star rating
Research CMS star ratings
The CMS has implemented a 5-star rating system to measure the quality of health and drug services provided by Medicare Advantage and Medicare Part D (prescription drug) plans.
Every year, the CMS releases these star ratings and additional data to the public.
The CMS ratings can be a great place to start when shopping around for the best Medicare Advantage plan in your state. Consider researching these plans for more information on what coverage is included and how much it costs.
To see all available Medicare Part C and D 2025 star ratings, visit CMS.gov and download the 2025 Medicare Star Ratings Data Table.
Consider your coverage priorities
All Medicare Advantage plans cover what Original Medicare covers — this includes hospital coverage (Part A) and medical coverage (Part B).
When you choose a Medicare Advantage plan, you first want to consider what type of coverage you need in addition to the coverage above.
Most Medicare Advantage plans offer one, if not all, of these additional types of coverage:
prescription drug coverage
dental coverage, including yearly exams and procedures
vision coverage, including yearly exams and vision devices
hearing coverage, including exams and hearing devices
fitness memberships
medical transportation
additional healthcare perks
Finding the best Medicare Advantage plan means making a checklist of the services you want to receive coverage for. You can then take your coverage checklist to Medicare's find a plan tool and compare plans that cover what you need.
If you find a plan that looks good for you, don't be afraid to call the company to ask if they offer any additional coverage or perks.
Determine your budget and potential healthcare costs
One of the most important things to consider when choosing the best Medicare Advantage plan is how much it will cost you. The find a plan tool lists the following cost information with the plans:
monthly premium
Part B premium
in-network yearly deductible
drug deductible
in- and out-of-network out-of-pocket max
copays and coinsurance
To get a starting estimate of your yearly costs, consider the premium, deductible, and out-of-pocket max. Any deductible listed is the amount you'll owe out of pocket before your insurance begins to pay out. Any out-of-pocket max listed is the maximum amount you will pay for the services throughout the year.
When estimating your plan costs, consider these costs plus how often you will need to refill prescription drugs or make office visits.
If you require specialist or out-of-network visits, include those potential costs in your estimate as well. Remember that your amount may be lower if you receive financial assistance from the state.
Review other benefits you may already have
If you already receive other types of healthcare benefits, this may factor into what kind of Medicare Advantage plan you'll need.
For example, if you already receive Original Medicare and have opted to add Part D or Medigap, many of your needs may already be covered.
However, you can always do a coverage comparison to determine whether a Medicare Advantage plan would work better or be more cost-effective for you.
What Medicare Advantage plans are available?
When beginning your search for a Medicare Advantage (Part C) plan, it's important to know the differences between each type of plan.
You'll probably see some or all of the following types of plans when reviewing your options:
Health Maintenance Organization (HMO) plans: HMO plans are primarily focused on in-network healthcare services.
Preferred Provider Organization (PPO) plans: PPO plans charge different rates depending on whether the services are in or out of network. (A 'network' is a group of providers who contract to provide services for the specific insurance company and plan.) PPO plans may provide more options to receive out-of-network care.
Private Fee-for-Service (PFFS) plans: PFFS plans let you receive care from any Medicare-approved provider who will accept the approved fee from your plan.
Special Needs Plans (SNPs): SNPs offer additional help for medical costs associated with specific chronic health conditions.
Medicare Savings Account (MSA) plans: MSA plans combine a high-deductible health plan with a medical savings account.
Each plan offers options to accommodate your healthcare needs.
For example, if you have chronic health conditions, SNPs are designed to help alleviate some long-term costs. On the other hand, a PFFS or MSA plan might be beneficial if you travel and need to see out-of-network healthcare professionals.
When do you sign up for a Medicare Advantage plan?
The Medicare enrollment process can begin as early as 3 months before you or your loved one turns 65 years old. This is the best time to apply, as it will ensure that you receive coverage by your 65th birthday.
You can wait to apply for Medicare until the month of your 65th birthday or the 3 months following your birthday. However, coverage can be delayed if you wait, so try to apply early.
If you decide not to enroll in a Medicare Advantage plan when you first turn age 65, you have another chance during Medicare's annual open enrollment period.
From October 15 through December 7 each year, you can switch from Original Medicare to Medicare Advantage. You can also switch from one Medicare Advantage plan to another or add, remove, or change a Part D plan.
The takeaway
There are many factors that can influence which Medicare Advantage plan you choose. Consider the CMS star rating, your priorities and healthcare needs, how much you can afford, and what type of insurance you currently have.
It's important to enroll in Medicare before you turn age 65 to ensure that you don't go without medical coverage. Don't forget that you have the power to shop around for the best Medicare Advantage plan that fits all your needs.
The information on this website may assist you in making personal decisions about insurance, but it is not intended to provide advice regarding the purchase or use of any insurance or insurance products. Healthline Media does not transact the business of insurance in any manner and is not licensed as an insurance company or producer in any U.S. jurisdiction. Healthline Media does not recommend or endorse any third parties that may transact the business of insurance.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Bloomberg
13 minutes ago
- Bloomberg
UnitedHealth Cuts Commissions on Some Medicare Advantage Plans
UnitedHealth Group Inc. is cutting commissions for brokers on some Medicare Advantage plans, according to documents reviewed by Bloomberg News, a move that appears designed to discourage agents from selling those plans. The decision comes as UnitedHealth grapples with high costs in Medicare Advantage that derailed its financial outlook and sent its share price tumbling. By steering brokers away from selling some of these plans, the insurance giant could ultimately lower its costs.

Associated Press
20 minutes ago
- Associated Press
‘Gas station heroin' is technically illegal and widely available. Here are the facts
WASHINGTON (AP) — Health officials want you to think twice before buying one of those brightly colored little bottles often sold at gas stations, convenience stores and smoke shops. Sometimes called 'gas station heroin,' the products are usually marketed as energy shots or cognitive supplements but actually contain tianeptine, an unapproved drug that can be addictive and carries risks of serious side effects. U.S. poison control centers have reported a steady rise in calls linked to the drug for more than a decade. And last month the Food and Drug Administration sent a warning to health professionals about 'the magnitude of the underlying danger or these products.' Here's what to know about gas station heroin. How are these products sold in the U.S.? Tianeptine is approved in a number foreign countries as an antidepressant, usually as a low-dose pill taken three times a day. But it has never been approved by the FDA for any medical condition in the U.S. Additionally, the drug cannot legally be added to foods and beverages or sold as a dietary supplement — something the FDA has repeatedly warned U.S. companies about. Still, under-the-radar firms sell tianeptine in various formulas, often with brand names like Zaza, Tianaa, Pegasus and TD Red. Although that is technically illegal, the FDA does not preapprove ingredients added to supplements and beverages. 'It's kind of this grey area of consumer products, or supplements, where the contents are not regulated or tested the way they would be with a medication,' said Dr. Diane Calello of the New Jersey Poison Information and Education System. Last year, Calello and her colleagues published a study documenting a cluster of emergency calls in New Jersey tied to a flavored elixir called Neptune's Fix. People experienced distress, rapid heartbeat, low blood pressure and seizures after drinking it. More than a dozen of the 20 patients had to be admitted for intensive care. Why use these products? Many tianeptine products claim— without evidence or FDA approval— to help users treat medical conditions, including addiction, pain and depression. In 2018, the FDA issued a warning letter to the maker of a product called Tianna, which claimed to provide 'an unparalleled solution to cravings for opiates.' While tianeptine is not an opioid, the drug binds to some of the same receptors in the brain, which can temporarily produce effects akin to oxycodone and other opioids. Tianeptine also carries some of the same physiological risks of opioids, including the potential to dangerously depress breathing. 'That's what tends to get people into trouble,' said Dr. Hannah Hays of Nationwide Children's Hospital in Columbus, Ohio. 'They use it for opioid-like effects or to self-treat opioid withdrawal and that can lead to slow breathing and problems like that.' People dealing with opioid addiction, pain, depression, anxiety and other conditions should see a health professional to get a prescription for FDA-approved treatments, Hays said. Is tianeptine use going up? Experts aren't sure but national figures show a big rise in emergency calls involving the drug. Calls to poison control centers increased 525% between 2018 and 2023, according to a data analysis published earlier this year. In about 40% of cases, the person had to seek medical care, with more than half of them needing critical care. One explanation for the rise in calls is simply that more Americans are using the products. But experts also say that the products are triggering more emergencies as they become more potent and dangerous. And the researchers in New Jersey who analyzed Neptune's Fix found that the liquid also contained synthetic cannabis and other drugs. 'You never quite know what's in that bottle,' Calello said. 'It's important for people to know that even if they have used a product before, they could get a bottle that contains something very different from what they're looking for.' Are there policies that could reduce tianeptine use? Tianeptine is not included in the federal Controlled Substances Act, which bans or restricts drugs that have no medical use or have a high potential for abuse, such as heroin, LSD and PCP. But about a dozen states have passed laws prohibiting or restricting tianeptine, including Alabama, Georgia, Michigan, Minnesota, Ohio and Tennessee. In some cases, those laws have led to more cases of withdrawal among users of tianeptine, which can be chemically addictive. But state data also shows some success in reducing harm tied to the drug. Until recently, Alabama had the highest rate of tianeptine-related calls in the southern U.S., which increased more than 1,400% between 2018 to 2021. But after the state restricted tianeptine in 2021 calls began modestly decreasing while calls across other southern states continued to climb. ___

Associated Press
27 minutes ago
- Associated Press
Second patient death reported with gene therapy for muscular dystrophy
WASHINGTON (AP) — Shares of Sarepta Therapeutics plunged Monday after the biotech drugmaker reported a second death in connection with its gene therapy for muscular dystrophy. Sarepta reported the death over the weekend and provided additional details about its response, which includes pausing shipments of the therapy, Elevidys, for older patients who are no longer able to walk. The one-time treatment is approved for children with a genetic variant of Duchenne's muscular dystrophy, which causes weakness, loss of mobility and early death in males. Elevidys is the first gene therapy approved in the U.S. for the rare muscle-wasting condition, but it has faced scrutiny since its accelerated approval in 2023. The second death, like an earlier one reported in March, occurred in a teenage boy who suffered a fatal case of acute liver injury, a known side effect of the therapy. Older patients receive a larger dose of the therapy. Sarepta said it would pause a study in those patients and assemble an expert panel to recommend new safety protocols for taking the drug. Those changes are expected to include increased use of immune-system suppressing drugs, company executives said Monday. The liver injury associated with the therapy is thought to be connected to the immune system's response. Sarepta said it was cooperating with the Food and Drug Administration, which would have to sign off on any changes to the product's use. Elevidys received expedited approval despite concerns from some FDA scientists about its effectiveness in treating Duchenne's. The FDA granted full approval last year and expanded the therapy's use to patients 4 years and older, regardless of whether they are still able to walk. Previously it was only available for younger patients who were still walking. Shares of the Cambridge, Massachusetts-based company fell more than 42% to close at about $21 in trading. Wall Street analysts speculated that FDA officials, including new vaccine chief Dr. Vinay Prasad, might impose more restrictions on the drug or even block its use. Prasad has been highly critical of the therapy since its approval under the agency's previous leadership. 'Now with two deaths reported in this segment of the market, it seems incrementally more possible that the FDA could step in and remove the therapy from the market in non-ambulatory patients,' said Leerink Partners analyst Joseph Schwartz, in a Sunday research note. Elevidys uses a disabled virus to insert a replacement gene for producing dystrophin into patient cells. It costs $3.2 million for a one-time infusion. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.